Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Galmed Pharmaceuticals ( (GLMD) ) just unveiled an announcement.
On May 6, 2025, Galmed Pharmaceuticals announced significant results from oncology studies indicating that their drug Aramchol enhances the effects of Bayer’s Regorafenib in gastrointestinal cancer models. The study, conducted at Virginia Commonwealth University, showed that the combination significantly reduced hepatic tumor growth in mice and is set to progress to a Phase 1b clinical trial in late 2025. This development positions Galmed to potentially offer a cost-effective first-line treatment for liver and colorectal cancers, advancing their oncology program alongside their Semaglutide GLP-1 development.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.
Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for cardiometabolic diseases and gastrointestinal oncological therapeutics. The company is primarily known for its work on Aramchol, a drug aimed at treating liver diseases, and is expanding its focus to include oncological indications.
Average Trading Volume: 1,967,773
Technical Sentiment Signal: Sell
Current Market Cap: $2.82M
See more data about GLMD stock on TipRanks’ Stock Analysis page.